Abstract: The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.

Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.

Abstract: The invention provides for the use of deep sequencing of the T-cell receptor beta CDR3 to identify, then track donor specific and/or recipient specific T cells in blood, urine and/or end-organs of transplant recipients.

Abstract: The present invention relates to methods and kits for identifying effector regulatory T cells. In particular the present invention relates to use of CD15s as a biomarker for eTreg cells. The present invention also relates to a method for identifying effector Treg cells (eTreg) in a fluid sample comprising the steps of i) detecting the cell surface expression of CD4, CD25, CD127 and CD15s markers on the cell population contained in the fluid sample and ii) concluding that the cells expressing CD4, CD25, CD127 at low levels and CD15s are the effector Treg cells. The present invention also relates to a method for identifying effector Treg cells (eTreg) in a tissue sample comprising the steps of i) detecting the cell expression of CD4, CD25, Foxp3 and CD15s markers and ii) concluding that the cells expressing CD4, CD25, Foxp3 and CD15s are the effector Treg cells.

Abstract: This invention relates to the field of immunology and more specifically relates to antiphytase monoclonal antibodies and immunoassay methods for the detection of a phytase from or derived from Aspergillus niger (phyA2) phytase, in particular, EH10a, FA7, AF9a and CC1 antiphytase antibodies. The invention further relates to hybridoma cell lines that produce antiphytase monoclonal antibodies.

Abstract: Methods and apparatuses for measuring the concentration of functional proprotein convertase subtilisin/kexin type 9 (PCSK9). A method of measuring functional PCSK9 in a sample is provided, by contacting the sample with a PCSK9-binding agent capable of binding to the LDL-R-binding region of a PCSK9; and measuring the amount of functional PCSK9 from the sample bound to the binding agent. Diagnostic methods, kits, and reagents for using the method are also provided.

Abstract: The present invention relates to BTK occupancy assays.

Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.

Abstract: The present invention relates to methods for predicting and treating/preventing bone metastases in prostate cancer patients. In particular, the present invention relates to a method for predicting the occurrence of bone metastases in a prostate cancer patient comprising i) determining the level of expression of ERR? in a prostate tumor sample obtained from the patient, ii) comparing the level determined at step i) with a predetermined reference value and iii) concluding that there is a high risk that the patient develops bone metastases when the level determined at step i) is higher than the predetermined reference value or concluding that there is a low risk that the patient develops bone metastases when the level determined at step i) is lower than the predetermined reference value.

Abstract: Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.

Abstract: The present invention provides assays and methods for predicting the survival of a subject having colorectal cancer (CRC), thereby determining whether the subject will have a good prognosis or poor prognosis. The present invention also provides assays and methods for predicting therapeutic efficacy and/or response to anti-cancer therapeutics in a subject having CRC, thereby selecting a therapeutic regimen to which the subject is likely to be responsive.

Abstract: The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

Abstract: The present invention is based, at least in part, on the discovery of biomarkers identified herein which are associated with cutaneous T-cell lymphoma (CTCL). Accordingly, the present invention provides methods for diagnosing CTCL, e.g., early stage CTCL, including mycosis fungoides (MF) and Sézary syndrome (SS), and to distinguish CTCL from other skin disorders.

Abstract: Disclosed herein are isobaric labeling reagent sets useful for multiplexed quantitation of peptides. The isobaric labeling reagent sets include a collection of at least two isobaric labeling reagents having first and second reporter groups with the same nominal mass but different isotopic substitutions and consequently different exact masses. Mass spectrometric analysis of the labeled samples is performed using a mass analyzer, such as an Orbitrap mass analyzer, capable of adequately resolving the ions of the first and second reporter groups. Reagent sets of the foregoing description may provide a degree of multiplexing in reporter ion quantitation experiments that is expanded relative to conventional labeling reagent sets, thereby reducing the number of chromatographic runs required for analysis and improving sample throughput.

Abstract: This disclosure provides methods for generating super-resolution patterns of molecules on substrates.

Abstract: Secretome profiling improves the pregnancy success rate of in vitro fertilization processes, while reducing the risk of multiple births.

Abstract: Mycolic acid antigen containing liposomes, and an electrode immobilised antigens of tuberculous mycobacterial origin are produced. A diagnostic sample from a human suspected of having tuberculosis is diluted and divided into first and second samples. A control sample comprising the first sample and a redox probe is exposed to the liposomes. A test sample comprising the second sample and a redox probe is exposed to liposomes not containing mycolic acid antigens. The control sample is contacted with the immobilised antigens to allow antibodies therein to bind to the antigens. The test sample is contacted with the immobilised antigens to allow any antibodies therein to bind to the antigens. The degree of binding in the samples is compared by electrochemical impedance spectroscopy. Any observed lesser binding by the control sample is an indicator of antibodies to the antigens in the diagnostic sample, indicating tuberculosis in the human.

Abstract: Provided are a method for identifying the presence or likelihood of autoimmune arthritis, the method comprising detecting (1) an anti-ribosomal protein L23a antibody or (2) ribosomal protein L23a-reactive CD4+ T cells in a sample derived from a subject; and a method for screening for a substance that inhibits the activation of autoimmune arthritogenic T cells, the method comprising the steps of bringing a test substance into contact with ribosomal protein L23a-reactive T cells, bringing the T cells into contact with ribosomal protein L23a or a fragment thereof, measuring the level of a proinflammatory cytokine secreted from the T cells, and analyzing the test substance-dependent change in the secretion level of the proinflammatory cytokine.

Abstract: The present invention relates to a method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk providing a solution to the problems stated in the state of the art since it provides a method which allows making a prognosis of the number of reactions that will be produced during oral immunotherapy (OIT) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during OIT against proteins in cow's milk and/or the need for pre-medication during OIT in a human subject.

Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.

Abstract: The present invention relates to a composition for treating chronic inflammatory pain containing a pyruvate dehydrogenase kinase (PDK) inhibitor as an active ingredient and a composition for diagnosing chronic inflammatory pain containing a formulation measuring an expression level of mRNA of a PDK gene or a PDK protein. The PDK inhibitor of the present invention reduces an inflammatory response in an animal model where chronic inflammatory pain is induced and diminishes hindpaw edema and pain behaviors. Thus, the PDK inhibitor of the present invention can be useful for treating chronic inflammatory pain. Also, the PDK inhibitor of the present invention can be used for diagnosing chronic inflammatory pain by measuring the PDK expression level, since the PDK expression increases when chronic inflammatory pain is induced.

Abstract: Proteinuria markers and methods for their use are provided. These markers find many uses, including in diagnosing proteinuria, prognosing proteinuria, and treating proteinuria. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided.

Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

Abstract: The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, using the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No.2) or a partial peptide or fragment thereof. The invention further relates to a diagnostic device and a kit for carrying out the method.

Abstract: Methods of detecting A? oligomers, such as may be present in a biological sample are described. The methods include detection using flow cytometry, detection using synthetic A? oligomers and/or in vitro methods detecting A? oligomers associated with cells.

Abstract: The present invention relates to novel diagnostic, prognostic, predictive and pharmacodynamic properties with regard to amyotrophic lateral sclerosis (ALS) and/or Parkinson's disease (PD) with and without dementia components. The methods described herein will prove very useful in the development of diagnostic as well as treatment strategies for patients with amyotrophic lateral sclerosis (ALS) and/or Parkinson's disease (PD).

Abstract: Methods for identifying metabolic signatures in blood plasma which are unique to autism are described herein. Samples are analyzed using multiple chromatographic-mass spectrometry-based techniques to orthogonally measure a broad range of small molecular weight metabolites differentially produced in autistic patient samples versus non-autistic control samples. These individual metabolites or a panel of such metabolites serve as metabolic signatures of autism. Such metabolic signatures are used in diagnostic methods to accurately identify individuals with autism spectrum disorder (ASD).

Abstract: The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for A? amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

Abstract: The present invention provide water soluble polyfluorenes functionalized with glucuronic acid useful in sensing bilirubin in aqueous medium and process for preparation thereof. The invention further deals with detecting bilirubin in human serum samples in the range from normal (<25 ??ioI/L˜1.2 mg/dL) human bilirubin level to jaundiced bilirubin level (>50 ??ioI/L˜2.5 mg/dL). This is a fluorescence turn-off mode of detection where blue fluorescence of polymer quenches and becomes colorless. The water soluble polyfluorenes functionalized with glucuronic acid can detect free bilirubin in the range from 1×1O?4M to 1×10?7M moles in aqueous and buffer media as a change in the fluorescence signal.

Abstract: Diagnostic and therapeutic agents for pulmonary arterial hypertension (PAH) are provided. Circulating microparticles (MPs) and/or the expression level of GPR75 are significantly increased in PAH-PASMC, but not normal PASMC, thus, providing a non-invasive diagnostic method for PAH. Furthermore targeting MPs and/or GPR75 with specific antibodies, inverse agonists or antagonists is a strategy to treat PAH.

Abstract: Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample.

Abstract: Provided is a compound useful as a polyvalent metal ion sensor for calcium ions or the like which is capable of reversible sensing and of being integrated into a device, and an ion sensor using the compound. A copolymer comprising: a repeating unit (A) having a carboxyl group on a side chain thereof and a repeating unit (B) having a carboxylate group having an ester residue exhibiting an aggregation-induced emission capability on a side chain thereof.

Abstract: The present invention relates to methods and compositions for preventing or inhibiting pathogenic bacterial infections in a subject caused by pathogenic bacteria expressing a MAM polypeptide by administering to a subject a composition comprising a MAM polypeptide or a non-pathogenic bacterium expressing a MAM polypeptide, or a combination thereof.

Abstract: A computer-based method for determining a prediction of risk and/or an indication of extent of coronary stenosis in a human subject, comprises the steps of: (a) inputting the level of at least one cholesteryl ester measured in a blood sample collected from said subject; and then (b) inputting the age and gender of said subject; and then (c) generating in said computer from said cholesteryl ester level input, said age input and said gender input a prediction of risk and/or an indication of extent of coronary stenosis in said subject. Systems and methods are also described.

Abstract: Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Abstract: Techniques are disclosed relating to assay configuration. Assay devices are often used to determine characteristics of test samples, e.g., using polymerase chain reaction (PCR) or Deoxyribonucleic Acid (DNA) melt techniques. Various disclosed techniques allow detailed specification of assay parameters. This may allow user modification of assays and/or assay development by third parties. In embodiments in which assay parameters are specified using a separate device, these techniques may reduce validation requirements resulting from modified assays. In some embodiments, assay configuration information that may be added/removed/modified may include: a sequence of operations, parameters for the sequence of operations, data processing parameters, call logic rules/dependencies, and/or reporting rules.

Abstract: A measurement container supply device A supply section transfers the measurement container to the predetermined supply position includes a holding section (50) that holds the measurement container, and the holding section (50) has a first groove (52) that is formed to have a width that corresponds to the outer diameter of a body of the measurement container, and a second groove (54) that is formed to have a width that corresponds to the outer diameter of a neck of the measurement container. When the holding section (50) holds the measurement container, the first groove (52) comes in contact with the outer circumferential surface of the body, the second groove (54) comes in contact with the outer circumferential surface of the neck, and a step (56) that is formed by the first groove (52) and the second groove (54) comes in contact with a step that is formed by the body and the neck.

Abstract: A device for container storing is presented. The device comprises storage with at least one storing level including a pipetting storing level for fluid pipetting. Each storing level has storing positions having a container holder to detachably hold at least one container. A handler is movable with respect to the storage for transferring containers with respect to the storing positions. A storing position of the pipetting storing level includes a flat spring to bias a container against the container holder. The flat spring has a through hole to provide a pipette access to a lid of the container. A system for pipetting is also presented, comprising the device and a pipettor movable with respect to the pipetting storing level with at least one pipette for pipetting contained in a container stored in the pipetting storing level. The pipette has a pipette tip to penetrate a lid of the container.

Abstract: The invention provides an MEMS device. The MEMS device includes: a substrate, a proof mass, a spring, a spring anchor, a first electrode anchor, and a second electrode anchor, a first fixed electrode and a second fixed electrode. The proof mass is connected to the substrate through the spring and the spring anchor. The proof mass includes a hollow structure inside, and the spring anchor, the first electrode anchor, and the second electrode anchor are located in the hollow structure. The proof mass and the first fixed electrode form a first capacitor, and the proof mass and the second fixed electrode form a second capacitor. There is neither any portion of the proof mass nor any portion of any fixing electrode located between the first electrode anchor, second electrode anchor, and the spring anchor.

Abstract: A rotational speed measuring device for measuring the rotational speed on coaxially arranged drive shafts is described, wherein a first drive shaft is formed as an inner shaft in a second drive shaft embodied as a hollow shaft. The hollow shaft has at least one opening and a rotational speed encoder which is arranged on the inner shaft and can be detected through the opening of the hollow shaft. A rotational speed sensor is arranged on the outer side of the hollow shaft and is configured to pick up the rotational speed on the rotational speed encoder. A corresponding method for measuring the rotational speed on coaxially arranged drive shafts is also disclosed.

Abstract: A method of determining, with a processing device, an instantaneous speed of an arrow shot from a bow having a bow string is provided, the arrow shot at a target having a target-face. The method includes recording a signal that includes a first peak occurring substantially at a start of a free flight of the arrow and a second peak occurring substantially at a moment of impact of the arrow with the target, the start of the free-flight occurring when a proximate end of the arrow reaches substantially a neutral position of the bow string; processing the signal to determine a duration of the free flight of the arrow; determining a distance between a location from which the arrow is loosed and a location of the target-face; and determining the instantaneous speed of the arrow, at least in part, by employing each of the duration of the free flight and the distance.

Abstract: An approach is provided for adaptive display and filtering of sensors and sensor data. A sensor manager determines one or more signals associated with one or more sensors. The sensor manager then processes and/or facilitates a processing of the one or more signals for comparison against one or more predetermined signals. The sensor manager determines one or more parameters for one or more filters based, at least in part, on the comparison, wherein the one or more filters operate, at least in part, on the one or more sensors, one or more other signals determined form the one or more sensors, or a combination thereof.

Abstract: Described herein is a microelectromechanical detection structure, provided with: a substrate having a top surface extending in a plane; a detection-electrode arrangement; an inertial mass, suspended above the substrate and the detection-electrode arrangement; and elastic elements, coupling the inertial mass to a central anchorage element fixed with respect to the substrate, in such a way that it is free to rotate about an axis of rotation as a function of a quantity to be detected along a vertical axis, the central anchorage element being arranged at the axis of rotation. A suspension structure is coupled to the detection-electrode arrangement for supporting it, suspended above the substrate and underneath the inertial mass, and is anchored to the substrate via at least one first anchorage region; the fixed-electrode arrangement is anchored to the suspension structure via at least one second anchorage region.

Abstract: Described is a system which includes: a cable including: a first fiber optic interconnect to provide an input light; and a second fiber optic interconnect to provide an output light; and a first housing coupled to the cable, the first housing including: a first deflection circuit to deflect the input light received from the first fiber optic interconnect in response to a vibration or movement of the first housing; and a second housing coupled to the cable, the second housing including: a light source to generate the input light for transmission to the first deflection circuit via the first fiber optic interconnect; and a photo detector to receive the output light from the first deflection circuit via the second fiber optic interconnect.

Abstract: A method for testing the functionality of a rotation rate sensor, the rotation rate sensor including a substrate and a micromechanical structure oscillatory with respect to the substrate having a first drive element, a second drive element and at least one Coriolis element, the Coriolis element being excitable to at least one oscillation mode by the first drive element and/or by the second drive element, a detection signal being detected as a function of a force action to be detected on the Coriolis element, the rotation rate sensor being operable optionally in a normal mode or in a self-test mode, the first drive element and the second drive element being driven in the normal mode, characterized in that in the self-test mode, the first drive element or the second drive element is driven optionally exclusively.

Abstract: A method for calibrating a micromechanical sensor element, a piece of primary information describing a motion-state of the micromechanical sensor element being ascertained by the micromechanical sensor element during a first time interval, a piece of reference information describing the motion-state of the micromechanical sensor element being ascertained during a second time interval on the basis of an acoustic signal emitted by a sound source, the first time interval and the second time interval overlapping at least partially with respect to time, and the reference information being compared with the primary information in order to calibrate the micromechanical sensor element.

Abstract: A multi-axis microelectromechanical-systems (MEMS) inertial measurement unit (IMU) is fabricated in a vacuum sealed single packaged device. An FM vibratory gyroscope and an FM resonant accelerometer both for generating FM output signals is fabricated in the silicon chip using MEMS. A signal processor is coupled to the an FM vibratory gyroscope and to the FM resonant accelerometer for receiving the FM gyroscopic output signals and the FM accelerometer output signals. The signal processor generates simultaneous and decoupled measurement of input acceleration, input rotation rate, and temperature and/or temperature distribution within the IMU, self-calibration of the biases and scale factors of the IMU and its support electronics against temperature variations and other common mode errors, and reduction of the cross axis sensitivity by reducing acceleration errors in the gyroscope and rotation errors in the accelerometer.

Abstract: A method of correcting a vehicle speed displayed on a speedometer may include identifying a type of a control module in a vehicle. The method may additionally include determining a speed-related parameter to be revised based on the type of the control module. The method may additionally include receiving a reported vehicle speed and an actual vehicle speed. The method may additionally include determining a proportion between the reported vehicle speed and the actual vehicle speed. The method may additionally include determining a corrected value for the speed-related parameter based on the proportion between the reported vehicle speed and the actual vehicle speed. The method may additionally include detecting an end of a drive cycle. The method may additionally include transferring the corrected value of the speed-related parameter to update the control module after detecting the end of the drive cycle.

Abstract: This invention relates to a metrological scanning probe microscope system combining an SPM which employs an optical lever arrangement to measure displacement of the probe indirectly with another SPM which measures the displacement of the probe directly through the use of an interferometric detection scheme.